A1 Refereed original research article in a scientific journal

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer – The NORDIC-VII Study



Subtitle: The NORDIC-VII Study

Authors: Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T

Publisher: AMER SOC CLINICAL ONCOLOGY

Publication year: 2012

Journal: Journal of Clinical Oncology

Journal name in source: JOURNAL OF CLINICAL ONCOLOGY

Journal acronym: J CLIN ONCOL

Volume: 30

Issue: 15

First page : 1755

Last page: 1762

Number of pages: 8

ISSN: 0732-183X

DOI: https://doi.org/10.1200/JCO.2011.38.0915


Abstract
Cetuximab did not add significant benefit to the Nordic FLOX regimen in first-line treatment of mCRC. J Clin Oncol 30:1755-1762. (c) 2012 by American Society of Clinical Oncology



Last updated on 2024-26-11 at 16:07